Fahnen flattern vor der Evonik Hauptverwaltung an der Rellinghauser Straße 11 in Essen, DeutschlandFlags flutter in front of Evonik's headquarters at Rellinghauser Strasse 11 in Essen, Germany
Press Release

November 24, 2025

Evonik to showcase enhanced Ecobiol® probiotic at Poultry India 2025

•     Updated Ecobiol® probiotic for faster gut health support

•     Now with 46% faster outgrowth compared to competitor products

•     Comprehensive portfolio for poultry production

Evonik will present its latest innovations for sustainable poultry production at Poultry India 2025. A key highlight will be the updated version of Ecobiol®, Evonik’s probiotic for poultry, now featuring an optimized outgrowth profile for faster onset of activity.

“With the updated Ecobiol®, we’re setting a new standard for probiotics in poultry nutrition,” says Dr. Marion Hax, head of the Specialty Nutrition product line at Evonik Animal Nutrition. “Its improved outgrowth profile ensures faster probiotic activity, supporting gut health and feed efficiency, and reflects our commitment to helping producers achieve reliable, sustainable performance.”

Ecobiol® is a natural, spore-forming probiotic based on Bacillus CECT 5940. Thanks to advanced fermentation technology, the improved Ecobiol® germinates up to 46% faster than competitor products, ensuring more active probiotic cells are available in the upper small intestine. This rapid colonization supports gut health, enhances feed efficiency, improves nutrient absorption, and delivers consistent performance across diverse production systems.

In addition to Ecobiol®, Evonik will feature its amino acids portfolio for poultry, including MetAMINO® (DL-methionine). Methionine is the first limiting amino acid in poultry nutrition. MetAMINO® improves feed efficiency while helping to conserve valuable resources. Its product carbon footprint is approximately 35 percent lower than the calculated global industry average*.

The company will also highlight specialty feed additives such as SpeoCare® and GuanAMINO®, as well as its analytical services and feeding concepts that help producers optimize efficiency and sustainability.

Evonik’s offering underscores its commitment to “Sciencing the Global Food Challenge” — developing science-based solutions that enable healthier animals and cost-effective production, while minimizing the environmental impact of livestock farming.

Evonik can be found at Poultry India 2025 in Hall 2, K11–K16 from 26-28 November, at Hitex Exhibition Complex, Hyderabad, India.

*Methodology for global industry average excluding Evonik: estimated internally by Evonik‘s market intelligence, technology and lifecycle assessment experts.  Industry methionine sources include DL-methionine, L-methionine and methionine hydroxy analogue (MHA). Global Warming Potential is estimated accounting for the higher bioavailability of methionine in MetAMINO® versus MHA.

Evonik: Leading beyond chemistry

Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €15.2 billion and earnings (adjusted EBITDA) of €2.1 billion in 2024. The common motivation of the approximately 32,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day.

About Advanced Technologies

The Advanced Technologies segment includes Evonik’s market-leading businesses that leverage technological expertise and process know-how. These businesses feature high-performance polymers and crosslinking agents, hydrogen peroxide and silica, as well as feed ingredients. In 2024, the segment generated sales of €6.1 billion with around 8,000 employees.

Disclaimer

In so far as forecasts or expectations are expressed in this release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.